| - |
Dabigatran |
Pradaxa® |
For the prevention of stroke and systemic embolism in atrial fibrillation |
NCPE Assessment Process Complete |
3rd June 2011 |
 |
| - |
Dabigatran |
Pradaxa® |
For the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery. |
NCPE Assessment Process Complete |
1st September 2008 |
|
| - |
Dabigatran |
Pradaxa® |
For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. |
NCPE Assessment Process Complete |
13th June 2014 |
|
| - |
Dabrafeib |
Tafinlar® |
For the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation. |
NCPE Assessment Process Complete |
24th June 2014 |
|
| - |
Dabrafenib |
Tafinlar® plus Mekinist® |
In combination with trametinib, is indicated for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection. |
NCPE Assessment Process Complete |
19th August 2020 |
|
| - |
Daclatasvir |
Daklinza® |
In combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4) |
NCPE Assessment Process Complete |
29th May 2015 |
|
| - |
Daclizumab |
Zinbryta® |
Indicated in adult patients for the treatment of relapsing forms of multiple sclerosis. |
Rapid review complete |
23rd November 2016 |
|
| - |
Dacomitinib |
Vizimpro® |
Indicated as monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. |
Rapid review complete |
13th May 2019 |
|
| - |
Dalbavancin |
Xydalba® |
Indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. |
Rapid review complete |
28th April 2017 |
|
| 24016 |
Dantrolene sodium hemiheptahydrate |
Agilus® |
In combination with adequate support measures, dantrolene sodium hemiheptahydrate is indicated for the treatment of malignant hyperthermia in adults and children of all ages. |
Rapid Review complete |
11th March 2025 |
|
| - |
Dapagliflozin |
Forxiga® |
Indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. Add-on combination therapy: In combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. |
Rapid review complete |
31st December 2013 |
|
| 22030 |
Dapagliflozin |
Forxiga® |
Indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. |
Rapid review complete |
14th March 2024 |
|
| 22040 |
Dapagliflozin |
Forxiga® |
For the treatment of chronic kidney disease |
Rapid review complete |
14th July 2022 |
|
| 23065 |
Dapagliflozin |
Forxiga® |
Dapagliflozin (Forxiga®) is indicated in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%. |
Rapid Review Complete |
14th March 2024 |
|
| - |
Daratumumab |
Darzalex® |
For the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. |
NCPE Assessment Process Complete |
13th March 2017 |
|
| - |
Daratumumab |
Darzalex® in combination with bortezomib and dexamethasone |
For the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
NCPE Assessment Process Complete |
15th March 2019 |
|
| - |
Daratumumab in combination with lenalidomide and dexamethasone |
Darzalex® |
For the treatment of adult patients with multiple myeloma wo have received at least one prior therapy. |
Rapid review complete |
27th November 2017 |
|
| 20025 |
Daratumumab |
Darzalex® |
In combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. |
NCPE Assessment Process Complete |
16th November 2021 |
|
| 21041 |
Daratumumab |
Darzalex® in combination with cyclophosphamide, bortezomib and dexamethasone |
For the treatment of adult patients with newly diagnosed systemic light chain amyloidosis. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 22039 |
Daratumumab |
Darzalex® |
In combination with lenalidomide (Revlimid®) and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 25029 |
Daridorexant |
Quviviq® |
Daridorexant (Quviviq®) for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning. |
Rapid Review Complete |
25th April 2025 |
|
| 20022 |
Darolutamide |
Nubeqa® |
For the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. |
NCPE Assessment Process Complete |
10th September 2021 |
|
| - |
Darunavir & cobicistat |
Rezolsta® |
Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. |
Rapid review complete |
8th January 2015 |
|
| - |
Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide |
Symtuza® |
For the treatment of HIV-1 in adults and adolescents. |
Rapid review complete |
26th October 2017 |
|
| - |
Darvadstrocel |
Alofisel® |
For the treatment of complex perianal fistulae in adult patients with non-active/ mildly active luminal Crohn’s Disease when fistulae have shown an inadequate response to at least one conventional or biologic therapy and should be used after conditioning of fistula. |
NCPE Assessment Process Complete |
24th September 2019 |
|
| - |
Decitabine |
Dacogen® |
For AML in patients who are >65yrs who are not candidates for standard induction therapy |
Rapid review complete |
21st December 2012 |
|
| - |
Defibrotide |
Defitelio® |
Indicated in adults, children and infants (>1month) for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy |
Rapid review complete |
15th July 2014 |
|
| - |
Degarelin |
Firmagon® |
For the treatment of prostate cancer |
Rapid review complete |
15th October 2009 |
|
| 20038 |
Delafloxacin |
Quofenix® |
For the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Rapid review complete |
19th November 2020 |
|
| - |
Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD |
Sativex® |
Indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy. |
NCPE Assessment Process Complete |
20th October 2023 |
|
| - |
Denosumab |
Prolia® |
For the Prevention of Osteoporotic Fractures in Postmenopausal Women |
NCPE Assessment Process Complete |
1st July 2010 |
|
| - |
Denosumab |
Xgeva® |
For the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland |
NCPE Assessment Process Complete |
8th December 2011 |
|
| 23030 |
Deucravacitinib |
Sotyktu® |
Deucravacitinib is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Rapid Review Complete |
14th March 2024 |
|
| - |
Dexamethasone Intravitreal Implant |
Ozurdex® |
Treatment of macular oedema following Retinal Vein Occlusion |
NCPE Assessment Process Complete |
16th March 2012 |
|
| - |
Dexmedetomidine |
Dexdor® |
For the treatment of ICU adult patients requiring light to moderate sedation |
Rapid Review Complete |
6th September 2011 |
|
| - |
Diclofenac |
Itami® |
For the local symptomatic and short-term treatment (max. 7 days) of pain in acute strains, sprains or bruises of the extremities following blunt trauma e.g. sports injuries in adolescents aged from 16 years and adults |
Rapid Review Complete |
17th January 2019 |
|
| - |
Dienogest |
Visanne® |
For the Treatment of Endometriosis |
Rapid Review Complete |
4th October 2010 |
|
| 23001 |
Difelikefalin |
Kapruvia® |
For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. |
NCPE Assessment Process Complete |
20th September 2024 |
|
| - |
Dimethyl fumarate |
Skilarence® |
For the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. |
Rapid Review Complete |
6th February 2018 |
|
| - |
Dimethyl fumarate |
Tecfidera® |
For the treatment of adult patients with relapsing remitting multiple sclerosis (MS) |
NCPE Assessment Process Complete |
16th January 2015 |
|
| __ |
Dinutuximab beta |
Qarziba® |
For the treatment of high-risk neuroblastoma in patients ≥ 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease. |
NCPE Assessment Process Complete |
22nd October 2018 |
|
| 21047 |
Diroximel fumarate |
Vumerity® |
For the treatment of adult patients with relapsing-remitting multiple sclerosis |
Rapid Review Complete |
16th December 2021 |
|
| - |
Dolutegravir |
Tivicay® |
In combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age. |
Rapid Review Complete |
13th March 2014 |
|
| - |
Dolutegravir/lamivudine |
Dovato® |
For the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. |
Rapid Review Complete |
27th August 2019 |
|
| - |
Dolutegravir/Rilpivirine |
Juluca® |
For the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. |
Rapid review complete |
12th July 2018 |
|
| - |
Doravirine |
Pifeltro® |
In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. |
Rapid review complete |
16th January 2019 |
|
| - |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate |
Delstrigo® |
For the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine or tenofovir |
Rapid review complete |
16th January 2019 |
|
| 24004 |
Dostarlimab |
Jemperli® |
Dostarlimab is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. |
NCPE assessment ongoing |
26th June 2025 |
|
| 21045 |
Dostarlimab |
Jemperli® |
Indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. |
NCPE Assessment Process Complete |
27th March 2023 |
|
| 23052 |
Doxylamine/pyridoxine |
Cariban® |
Doxylamine/pyridoxine (Cariban®) is indicated for the symptomatic treatment of nausea and vomiting during pregnancy in adults who do not respond to conservative management. |
Rapid Review Complete |
14th March 2024 |
|
